Optimisation of a potent and fast acting antimalarial class that is orally efficacious in vivo [ 2018 - ]

Research Grant

Researchers: Dr Brad Sleebs (Principal investigator) ,  A/Pr Justin Boddey ,  Dr Paul Gilson ,  Prof Alan Cowman ,  Prof Vicky Avery

Brief description Malaria is a devastating disease that results in 600 000 deaths annually. Current therapeutics used to combat malaria have a limited duration of use in the clinic due to the onset of resistance. We have identified a highly active antimalarial series that we propose to further develop to meet the prerequisites required for partnership with the Medicines for Malaria Venture (MMV) for progression into the clinic.

Funding Amount $683,916.00

Funding Scheme Development Grants

Notes Development Grant